<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34528073</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1460-2156</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>145</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>Brain : a journal of neurology</Title>
          <ISOAbbreviation>Brain</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibiting with-no-lysine kinases enhances K+/Cl- cotransporter 2 activity and limits status epilepticus.</ArticleTitle>
        <Pagination>
          <StartPage>950</StartPage>
          <EndPage>963</EndPage>
          <MedlinePgn>950-963</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awab343</ELocationID>
        <Abstract>
          <AbstractText>First-in-line benzodiazepine treatment fails to terminate seizures in about 30% of epilepsy patients, highlighting a need for novel anti-seizure strategies. It is emerging that impaired K+/Cl- cotransporter 2 (KCC2) activity leads to deficits in GABAergic inhibition and increased seizure vulnerability in patients. In neurons, the with-no-lysine (WNK) kinase-STE20/SPS1-related proline/alanine-rich (SPAK) kinase signalling pathway inhibits KCC2 activity via T1007 phosphorylation. Here, we exploit the selective WNK kinase inhibitor WNK463 to test the effects of pharmacological WNK inhibition on KCC2 function, GABAergic inhibition, and epileptiform activity. Immunoprecipitation and western blotting analysis revealed that WNK463 reduces KCC2-T1007 phosphorylation in vitro and in vivo. Using patch-clamp recordings in primary rat neurons, we further observed that WNK463 hyperpolarized the Cl- reversal potential, and enhanced KCC2-mediated Cl- extrusion. In the 4-aminopyridine slice model of acute seizures, WNK463 administration reduced the frequency and number of seizure-like events. In vivo, C57BL/6 mice that received intrahippocampal WNK463 experienced delayed onset of kainic acid-induced status epilepticus, less epileptiform EEG activity, and did not develop pharmaco-resistance to diazepam. Our findings demonstrate that acute WNK463 treatment potentiates KCC2 activity in neurons and limits seizure burden in two well-established models of seizures and epilepsy. In summary, our work suggests that agents which act to increase KCC2 activity may be useful adjunct therapeutics to alleviate diazepam-resistant status epilepticus.</AbstractText>
          <CopyrightInformation>© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Kathryn L</ForeName>
            <Initials>KL</Initials>
            <Identifier Source="ORCID">0000-0003-0079-9185</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abiraman</LastName>
            <ForeName>Krithika</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lucaj</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AstraZeneca-Tufts Laboratory of Basic and Translational Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ollerhead</LastName>
            <ForeName>Thomas A</ForeName>
            <Initials>TA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brandon</LastName>
            <ForeName>Nicholas J</ForeName>
            <Initials>NJ</Initials>
            <AffiliationInfo>
              <Affiliation>Neuroscience, BioPharmaceuticals R&amp;D, AstraZeneca, Boston, MA 02451, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deeb</LastName>
            <ForeName>Tarek Z</ForeName>
            <Initials>TZ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AstraZeneca-Tufts Laboratory of Basic and Translational Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maguire</LastName>
            <ForeName>Jamie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moss</LastName>
            <ForeName>Stephen J</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AstraZeneca-Tufts Laboratory of Basic and Translational Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC16BT, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R21 NS103865</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 MH118263</GrantID>
            <Acronym>MH</Acronym>
            <Agency>NIMH NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 NS111338</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS101888</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS087662</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS081986</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS108378</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Brain</MedlineTA>
        <NlmUniqueID>0372537</NlmUniqueID>
        <ISSNLinking>0006-8950</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027981">Symporters</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K3Z4F929H6</RegistryNumber>
          <NameOfSubstance UI="D008239">Lysine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q3JTX2Q7TU</RegistryNumber>
          <NameOfSubstance UI="D003975">Diazepam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003975" MajorTopicYN="N">Diazepam</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004827" MajorTopicYN="Y">Epilepsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013226" MajorTopicYN="Y">Status Epilepticus</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027981" MajorTopicYN="Y">Symporters</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">GABA</Keyword>
        <Keyword MajorTopicYN="N">KCC2</Keyword>
        <Keyword MajorTopicYN="N">diazepam</Keyword>
        <Keyword MajorTopicYN="N">epilepsy</Keyword>
        <Keyword MajorTopicYN="N">with-no-lysine kinase</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>7</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34528073</ArticleId>
        <ArticleId IdType="pmc">PMC9050525</ArticleId>
        <ArticleId IdType="doi">10.1093/brain/awab343</ArticleId>
        <ArticleId IdType="pii">6370956</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Yamada J, Okabe A, Toyoda H, Kilb W, Luhmann HJ, Fukuda A. Cl- uptake promoting depolarizing GABA actions in immature rat neocortical neurones is mediated by NKCC1. J Physiol. 2004;557(Pt 3):829–841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1665166</ArticleId>
            <ArticleId IdType="pubmed">15090604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Friedel P, Kahle KT, Zhang J, et al. . 
WNK1-regulated inhibitory phosphorylation of the KCC2 cotransporter maintains the depolarizing action of GABA in immature neurons. Sci Signal. 2015;8(383):ra65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26126716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee HH, Deeb TZ, Walker JA, Davies PA, Moss SJ. NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor-mediated currents. Nat Neurosci. 2011;14(6):736–743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3102766</ArticleId>
            <ArticleId IdType="pubmed">21532577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rivera C, Voipio J, Payne JA, et al. . 
The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature. 1999;397(6716):251–255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9930699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Deeb TZ, Lee HH, Walker JA, Davies PA, Moss SJ. Hyperpolarizing GABAergic transmission depends on KCC2 function and membrane potential. Channels (Austin). 2011;5(6):475–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3265795</ArticleId>
            <ArticleId IdType="pubmed">22082832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stein V, Hermans-Borgmeyer I, Jentsch TJ, Hubner CA. Expression of the KCl cotransporter KCC2 parallels neuronal maturation and the emergence of low intracellular chloride. J Comp Neurol. 2004;468(1):57–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14648690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moore YE, Kelley MR, Brandon NJ, Deeb TZ, Moss SJ. Seizing control of KCC2: a new therapeutic target for epilepsy. Trends Neurosci. 2017;40(9):555–571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28803659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Coull JA, Boudreau D, Bachand K, et al. . 
Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature. 2003;424(6951):938–942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12931188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cellot G, Cherubini E. GABAergic signaling as therapeutic target for autism spectrum disorders. Front Pediatr. 2014;2:70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4085902</ArticleId>
            <ArticleId IdType="pubmed">25072038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barmashenko G, Hefft S, Aertsen A, Kirschstein T, Kohling R. Positive shifts of the GABAA receptor reversal potential due to altered chloride homeostasis is widespread after status epilepticus. Epilepsia. 2011;52(9):1570–1578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21899534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huberfeld G, Wittner L, Clemenceau S, et al. . 
Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci. 2007;27(37):9866–9873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6672644</ArticleId>
            <ArticleId IdType="pubmed">17855601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stodberg T, McTague A, Ruiz AJ, et al. . 
Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. Nat Commun. 2015;6:8038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4569694</ArticleId>
            <ArticleId IdType="pubmed">26333769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saitsu H, Watanabe M, Akita T, et al. . 
Impaired neuronal KCC2 function by biallelic SLC12A5 mutations in migrating focal seizures and severe developmental delay. Sci Rep. 2016;6:30072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4951812</ArticleId>
            <ArticleId IdType="pubmed">27436767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sivakumaran S, Cardarelli RA, Maguire J, et al. . 
Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivo. J Neurosci. 2015;35(21):8291–8296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4444547</ArticleId>
            <ArticleId IdType="pubmed">26019342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kelley MR, Cardarelli RA, Smalley JL, et al. . 
Locally reducing KCC2 activity in the hippocampus is sufficient to induce temporal lobe epilepsy. EBioMedicine. 2018;32:62–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6020795</ArticleId>
            <ArticleId IdType="pubmed">29884458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hubner CA, Stein V, Hermans-Borgmeyer I, Meyer T, Ballanyi K, Jentsch TJ. Disruption of KCC2 reveals an essential role of K-Cl cotransport already in early synaptic inhibition. Neuron. 2001;30(2):515–524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11395011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woo NS, Lu J, England R, et al. . 
Hyperexcitability and epilepsy associated with disruption of the mouse neuronal-specific K–Cl cotransporter gene. Hippocampus. 2002;12(2):258–268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12000122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Uvarov P, Ludwig A, Markkanen M, et al. . 
A novel N-terminal isoform of the neuron-specific K–Cl cotransporter KCC2. J Biol Chem. 2007;282(42):30570–30576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17715129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Uvarov P, Ludwig A, Markkanen M, et al. . 
Coexpression and heteromerization of two neuronal K–Cl cotransporter isoforms in neonatal brain. J Biol Chem. 2009;284(20):13696–13704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2679471</ArticleId>
            <ArticleId IdType="pubmed">19307176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Neligan A, Shorvon SD. The history of status epilepticus and its treatment. Epilepsia. 2009;50(Suppl 3):56–68.</Citation>
        </Reference>
        <Reference>
          <Citation>
Deeb TZ, Maguire J, Moss SJ. Possible alterations in GABA(A) receptor signaling that underlie benzodiazepine-resistant seizures. Epilepsia. Dec 2012;53(Suppl 9):79–88.</Citation>
        </Reference>
        <Reference>
          <Citation>
Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59(2):205–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11843690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shorvon S. Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. Epilepsia. Oct 2011;52 (Suppl 8): 53–56.</Citation>
        </Reference>
        <Reference>
          <Citation>
Deshpande LS, Blair RE, Nagarkatti N, Sombati S, Martin BR, DeLorenzo RJ. Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus. Exp Neurol. 2007;204(2):705–713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2094113</ArticleId>
            <ArticleId IdType="pubmed">17289026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jones DM, Esmaeil N, Maren S, Macdonald RL. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res. 2002;50(3):301–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12200221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Feng HJ, Mathews GC, Kao C, Macdonald RL. Alterations of GABA A-receptor function and allosteric modulation during development of status epilepticus. J Neurophysiol. 2008;99(3):1285–1293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18216225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li X, Zhou J, Chen Z, Chen S, Zhu F, Zhou L. Long-term expressional changes of Na+–K+–Cl co-transporter 1 (NKCC1) and K+–Cl co-transporter 2 (KCC2) in CA1 region of hippocampus following lithium-pilocarpine induced status epilepticus (PISE). Brain Res. 2008;1221:141–146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18550034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Silayeva L, Deeb TZ, Hines RM, et al. . 
KCC2 activity is critical in limiting the onset and severity of status epilepticus. Proc Natl Acad Sci USA. 2015;112(11):3523–3528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4371976</ArticleId>
            <ArticleId IdType="pubmed">25733865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smalley JL, Kontou G, Choi C, et al. . 
Isolation and characterization of multi-protein complexes enriched in the K–Cl Co-transporter 2 from brain plasma membranes. Front Mol Neurosci. 2020;13:563091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7643010</ArticleId>
            <ArticleId IdType="pubmed">33192291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee HH, Walker JA, Williams JR, Goodier RJ, Payne JA, Moss SJ. Direct protein kinase C-dependent phosphorylation regulates the cell surface stability and activity of the potassium chloride cotransporter KCC2. J Biol Chem. 2007;282(41):29777–29784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17693402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Inoue K, Furukawa T, Kumada T, et al. . 
Taurine inhibits K+–Cl cotransporter KCC2 to regulate embryonic Cl homeostasis via with-no-lysine (WNK) protein kinase signaling pathway. J Biol Chem. 2012;287(25):20839–20850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3375508</ArticleId>
            <ArticleId IdType="pubmed">22544747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moore YE, Deeb TZ, Chadchankar H, Brandon NJ, Moss SJ. Potentiating KCC2 activity is sufficient to limit the onset and severity of seizures. Proc Natl Acad Sci USA. 2018;115(40):10166–10171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6176565</ArticleId>
            <ArticleId IdType="pubmed">30224498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rinehart J, Maksimova YD, Tanis JE, et al. . 
Sites of regulated phosphorylation that control K–Cl cotransporter activity. Cell. 2009;138(3):525–536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2811214</ArticleId>
            <ArticleId IdType="pubmed">19665974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kahle KT, Rinehart J, Lifton RP. Phosphoregulation of the Na–K–2Cl and K–Cl cotransporters by the WNK kinases. Biochim Biophys Acta. 2010;1802(12):1150–1158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3529164</ArticleId>
            <ArticleId IdType="pubmed">20637866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Los Heros P, Alessi DR, Gourlay R, et al. . 
The WNK-regulated SPAK/OSR1 kinases directly phosphorylate and inhibit the K+–Cl co-transporters. Biochem J. 2014;458(3):559–573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3940040</ArticleId>
            <ArticleId IdType="pubmed">24393035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alessi DR, Zhang J, Khanna A, Hochdörfer T, Shang Y, Kahle KT. The WNK–SPAK/OSR1 pathway: master regulator of cation–chloride cotransporters. Sci Signal. 2014;7(334):re3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25028718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamada K, Park H-M, Rigel DF, et al. . 
Small-molecule WNK inhibition regulates cardiovascular and renal function. Nat Chem Biol. 2016;12(11):896–898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27595330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kelley MR, Deeb TZ, Brandon NJ, Dunlop J, Davies PA, Moss SJ. Compromising KCC2 transporter activity enhances the development of continuous seizure activity. Neuropharmacology. 2016;108:103–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5337122</ArticleId>
            <ArticleId IdType="pubmed">27108931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Conway LC, Cardarelli RA, Moore YE, et al. . 

N-Ethylmaleimide increases KCC2 cotransporter activity by modulating transporter phosphorylation. J Biol Chem. 2017;292(52):21253–21263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5766942</ArticleId>
            <ArticleId IdType="pubmed">29092909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hartmann AM, Pisella LI, Medina I, Nothwang HG. Molecular cloning and biochemical characterization of two cation chloride cotransporter subfamily members of Hydra vulgaris. PLoS One. 2017;12(6):e0179968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5491111</ArticleId>
            <ArticleId IdType="pubmed">28662098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hablitz LM, Pla V, Giannetto M, et al. . 
Circadian control of brain glymphatic and lymphatic fluid flow. Nat Commun. 2020;11(1):4411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7468152</ArticleId>
            <ArticleId IdType="pubmed">32879313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferguson KT, Torr EE, Bernau K, Leet J, Sherris D, Sandbo N. The novel mTOR complex 1/2 inhibitor P529 inhibits human lung myofibroblast differentiation. J Cell Biochem. 2017;118(8):2241–2249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5568785</ArticleId>
            <ArticleId IdType="pubmed">28078713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
DeVos SL, Miller TM. Direct intraventricular delivery of drugs to the rodent central nervous system. J Vis Exp. 2013;(75):e50326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3679837</ArticleId>
            <ArticleId IdType="pubmed">23712122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pardridge WM. CSF, blood–brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016;13(7):963–975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27020469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee V, Maguire J. Impact of inhibitory constraint of interneurons on neuronal excitability. J Neurophysiol. 2013;110(11):2520–2535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3882765</ArticleId>
            <ArticleId IdType="pubmed">24027099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Richardson C, Rafiqi FH, Karlsson HK, et al. . 
Activation of the thiazide-sensitive Na+–Cl cotransporter by the WNK-regulated kinases SPAK and OSR1. J Cell Sci. 2008;121(Pt 5):675–684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18270262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Agez M, Schultz P, Medina I, et al. . 
Molecular architecture of potassium chloride co-transporter KCC2. Sci Rep. 2017;7(1):16452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5705597</ArticleId>
            <ArticleId IdType="pubmed">29184062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cardarelli RA, Jones K, Pisella LI, et al. . 
The small molecule CLP257 does not modify activity of the K(+)–Cl(–) co-transporter KCC2 but does potentiate GABAA receptor activity. Nat Med. 2017;23(12):1394–1396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7371006</ArticleId>
            <ArticleId IdType="pubmed">29216042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Abe Y, Furukawa K, Itoyama Y, Akaike N. Glycine response in acutely dissociated ventromedial hypothalamic neuron of the rat: New approach with gramicidin perforated patch-clamp technique. J Neurophysiol. 1994;72(4):1530–1537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7529820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jennings ML, Adame MF. Direct estimate of 1:1 stoichiometry of K(+)–Cl(–) cotransport in rabbit erythrocytes. Am J Physiol Cell Physiol. 2001;281(3):C825–832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11502559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu H, Che X, Tang J, et al. . 
The K(+)–Cl(–) cotransporter KCC2 and chloride homeostasis: potential therapeutic target in acute central nervous system injury. Mol Neurobiol. 2016;53(4):2141–2151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25941074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tang X, Drotar J, Li K, et al. . 
Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice. Sci Transl Med. 2019;11:503.</Citation>
        </Reference>
        <Reference>
          <Citation>
Loscher W, Puskarjov M, Kaila K. Cation–chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology. 2012;69:62–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22705273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fueta Y, Avoli M. Effects of antiepileptic drugs on 4-aminopyridine-induced epileptiform activity in young and adult rat hippocampus. Epilepsy Res. 1992;12(3):207–215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1396546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Avoli M, Psarropoulou C, Tancredi V, Fueta Y. On the synchronous activity induced by 4-aminopyridine in the CA3 subfield of juvenile rat hippocampus. J Neurophysiol. 1993;70(3):1018–1029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7901344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dreier JP, Zhang CL, Heinemann U. Phenytoin, phenobarbital, and midazolam fail to stop status epilepticus-like activity induced by low magnesium in rat entorhinal slices, but can prevent its development. Acta Neurol Scand. 1998;98(3):154–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9786610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dreier JP, Heinemann U. Regional and time dependent variations of low Mg2+ induced epileptiform activity in rat temporal cortex slices. Exp Brain Res. 1991;87(3):581–596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1783028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hamidi S, Avoli M. KCC2 function modulates in vitro ictogenesis. Neurobiol Dis. 2015;79:51–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4880462</ArticleId>
            <ArticleId IdType="pubmed">25926348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Delpire E, Baranczak A, Waterson AG, et al. . 
Further optimization of the K–Cl cotransporter KCC2 antagonist ML077: Development of a highly selective and more potent in vitro probe. Bioorg Med Chem Lett. 2012;22(14):4532–4535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3389279</ArticleId>
            <ArticleId IdType="pubmed">22727639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
East MP, Laitinen T, Asquith CRM. WNK kinases: an untapped opportunity to modulate ion transport. Nat Rev Drug Discov. 2020;19(12):828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33159187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McCormick JA, Ellison DH. The WNKs: Atypical protein kinases with pleiotropic actions. Physiol Rev. 2011;91(1):177–219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3035565</ArticleId>
            <ArticleId IdType="pubmed">21248166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Benson JA, Low K, Keist R, Mohler H, Rudolph U. Pharmacology of recombinant gamma-aminobutyric acidA receptors rendered diazepam-insensitive by point-mutated alpha-subunits. FEBS Lett. 1998;431(3):400–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9714551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2011;10(9):685–697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3375401</ArticleId>
            <ArticleId IdType="pubmed">21799515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci. 2005;6(3):215–229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15738957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kapur J, Coulter DA. Experimental status epilepticus alters gamma-aminobutyric acid type A receptor function in CA1 pyramidal neurons. Ann Neurol. 1995;38(6):893–900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2908242</ArticleId>
            <ArticleId IdType="pubmed">8526461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science. 2002;298(5597):1418–1421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12434059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kahle KT, Delpire E. Kinase-KCC2 coupling: Cl rheostasis, disease susceptibility, therapeutic target. J Neurophysiol. 2016;115(1):8–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4760510</ArticleId>
            <ArticleId IdType="pubmed">26510764</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
